Overactive bladder in males

Therapeutic Advances in Urology

Volumn 1, Issue 4, 2009, Pages 209-221

  Gomelsky, Alex ^a   Dmochowski, Roger R ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticholinergic; benign prostatic hypertrophy; overactive bladder

Indexed keywords

EID: 84993683469     PISSN: 17562872     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756287209350383     Document Type: Review

References (91)

1. Abrams, P. (1985) Detrusor instability and bladder outlet obstruction. Neurourol Urodyn 4: 317-328.
2. Abrams, P. (2005) Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Suppl 3): 8-16.
3. Abrams, P., Schulman, C.C. and Vaage, S. (1995) Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction– (symptomatic BPH). Br J Urol 76: 325-336.
4. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U. et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 37-49.
5. Abrams, P., Kaplan, S.A., De Koning Gans, H.J. and Millard, R. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999-1004.
6. Abrams, P., Chapple, C., Khoury, S., Roehrborn, C. and de la Rosette, J. (2008) Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 181: 1779-1787.
7. Andersson, K.E. (1993) Pharmacology of lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev 45: 253-308.
8. Andersson, K.E. (2003) Storage and voiding symptoms: pathophysiological aspects. Urology 62(Suppl 5B): 3-10.
9. Andersson, K.E. (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3: 46-53.
10. Athanasopoulos, A., Gyftopoulos, K., Giannitsas, K., Fisfis, J., Perimenis, P. and Barbalias, G. (2003) Combination treatment with an alpha blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169: 2253-2256.
11. Badawi, J.K. and Langbein, S. (2006) Selective beta-adrenoceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence. Pharmazie 61: 175-178.
12. Badawi, J.K., Li, H., Langbein, S., Kwon, S.T., Kamp, S. and Bross, S. (2006) Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol 62: 347-354.
13. Barry, M.J., Fowler Jr, F.J., O–Leary, M.P., Bruskewitz, R.C., Holtgrewe, H.L., Mebust, W.K. et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148: 1549-1557.
14. Bates, C.P., Whiteside, C.G. and Turner-Warwick, R. (1970) Synchronous cine-pressure-flow-cystourethrography with special reference to stress and urge incontinence. Br J Urol 42: 714-723.
15. Benner, J.S., Becker, R., Fanning, K., Jumadilova, Z., Bavendam, T. and Brubaker, L. (2009) Bother related to bladder control and health care setting behavior in adults in the United States. J Urol 181: 2591-2598.
16. Boselli, C., Govoni, S., Condino, A.M. and D–Agostino, G. (2001) Bladder instability: a reappraisal of classical experimental approaches and development of new therapeutic strategies. J Auton Pharmacol 21: 219-229.
17. Brading, A.F. (1997) A myogenic basis for the overactive bladder. Urology 50(6A Suppl): 57-67.
18. Burgio, K.L., Locher, J.L. and Goode, P.S. (2000) Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48: 370-374.
19. Chapple, C.R. and Roehrborn, C.G. (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49: 651-659.
20. Chapple, C.R., Carter, P., Christmas, T.J., Kirby, R.S., Bryan, J., Milroy, E.J. et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50-56.
21. Charlton, R.G., Morley, A.R., Chambers, P. and Gillespie, J.I. (1999) Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int 84: 953-960.
22. Christ, G.J., Day, N.S., Day, M., Zhao, W., Persson, K., Pandita, R.K. et al (2003) Increased connexin 43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol 284: R1241-R1248.
23. Daniel, E.E., Cowan, W. and Daniel, V.P. (1983) Structure bases for neural and myogenic control of human detrusor muscle. Can J Physiol Pharmacol 61: 1247-1273.
24. Debruyne, F.M.J., Witjes, W.P.J., Fitzpatrick, J., Kirby, R., Kirk, D. and Prezioso, D. (1996) The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 30: 369-376.
25. de Groat, W.C. (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147: S25-S40.
26. de Groat, W.C. and Theobald, R.J. (1976) Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents. J Physiol 259: 223-237.
27. Dmochowski, R.R. and Newman, D.K. (2007) Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 23: 65-76.
28. Drake, M.J., Mills, I.W. and Gillespie, J.I. (2001) Models of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 358: 401-403.
29. Elbadawi, A., Yalla, S.V. and Resnick, N.M. (1993a) Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 150: 1650-1656.
30. Elbadawi, A., Yalla, S.V. and Resnick, N.M. (1993b) Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 150: 1657-1667.
31. Elbadawi, A., Hailemariam, S., Yalla, S.V. and Resnick, N.M. (1997a) Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J Urol 157: 1802-1813.
32. Elbadawi, A., Hailemariam, S., Yalla, S.V. and Resnick, N.M. (1997b) Structural basis of geriatric voiding dysfunction. VII. Prospective ultrastructural/ urodynamic evaluation of its natural evolution. J Urol 157: 1814-1822.
33. Fujimura, T., Tamura, K., Tsutsumi, T., Yamamoto, T., Nakamura, K., Koibuchi, Y. et al (1999) Expression and possible functional role of the beta 3-adrenoceptor in human and rat detrusor muscle. J Urol 161: 680-685.
34. Gabella, G. and Uvelius, B. (1990) Urinary bladder of rat: fine structure of normal and hypertrophic musculature. Cell Tissue Res 262: 67-79.
35. Gormley, E.A., Griffiths, D.J., McCracken, P.N., Harrison, G.M. and McPhee, M.S. (1993) Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol Urodyn 12: 445-453.
36. Gosling, J.A., Kung, L.S., Dixon, J.S., Horan, P., Whitbeck, C. and Levin, R.M. (2000) Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol 163: 1349-1356.
37. Haferkamp, A., Mundhenk, J., Bastian, P.J., Reitz, A., Dorsam, J., Pannek, J. et al (2004) Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol 46: 799-805.
38. Hu, T.W., Wagner, T.H., Bentkover, J.D., LeBlanc, K., Zhou, S.Z. and Hunt, T. (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63: 461-465.
39. Igawa, Y., Yamazaki, Y., Takeda, H., Hayakawa, K., Akahane, M., Ajisawa, Y. et al (1999) Functional and molecular biological evidence for a possible beta 3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126: 819-825.
40. Irwin, D.E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S. et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306-1314.
41. Irwin, D.E., Milsom, I., Kopp, Z., Abrams, P., Artibani, W. and Herschorn, S. (2009) Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol(e-published 3 March 2009).
42. Jardin, A., Bensadoun, H., Delauche-Cavallier, M.C. and Attali, P. (1991) The BPH-ALF Group. (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457-1461.
43. Johnson II, T.M., Jones, K., Williford, W.O., Kutner, M.H., Issa, M.M. and Lepor, H. (2003) Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study trial. J Urol 170: 145-148.
44. Jumadilova, Z., Harris, H., del Aguila, M., Wagner, S., Boccuzzi, S., Bavendam, T. (2005) Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia. 2005 Annual ICS Meeting, Abstract #486.
45. Kaplan, S.A. (2006) Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 8(Suppl 4): S10-S17.
46. Kaplan, S.A., Walmsley, K. and Te, A. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273-2276.
47. Kaplan, S.A., Roehrborn, C.G., Rovner, E.S., Carlsson, M., Bavendam, T. and Guan, Z. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296: 2319-2328.
48. Kemmer, H., Mathes, A.M., Dilk, O., Groschel, A., Grass, C. and Stockle, M. (2009) Obstructive sleep apnea syndrome is associated with overactive bladder and urgency incontinence in men. Sleep 32: 271-275.
49. Klevmark, B. (1974) Motility of the urinary bladder in cats during filling at physiological rates. I. Intravesical pressure patterns studies by a new method of cystometry. Acta Physiol Scand 90: 565-577.
50. Koyne, K.S., Sexton, C.C., Irwin, D.E., Kopp, Z.S., Kelleher, C.J. and Milsom, I. (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101: 1388-1395.
51. Lee, J.Y., Kim, H.W., Lee, S.J., Koh, J.S., Suh, H.J. and Chancellor, M.B. (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int 94: 817-820.
52. Lee, K.S., Choo, M.S., Kim, D.Y., Kim, J.C., Kim, H.J., Min, K.S. et al (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334-1338.
53. Lee, S.W., Liong, M.L., Yuen, K.H., Liong, Y.V. and Krieger, J.N. (2007) Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy. Urol Int 78: 97-105.
54. Levin, R.M., Longhurst, P.A., Monson, F.C., Kato, K. and Wein, A.J. (1990) Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl 3: 9-26.
55. Liu, H., Liu, P., Mao, G., Chen, G., Wang, B., Qin, X. et al (2009) Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. Urology April 14[Epub ahead of print].
56. Lowe, F.C. (2004) Role of the newer alpha-adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26: 1701-1713.
57. McConnell, J.D., Roehrborn, C.G., Bautista, O.M., Andriole Jr, G.L., Dixon, C.M., Kusek, J.W. et al (2003) for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398.
58. Michel, M.C. and de la Rosette, J.J.M.C.H. (2005) Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 96(Suppl 1): 37-42.
59. Mills, I.W., Greenland, J.E., McMurray, G., McCoy, R., Ho, K.M., Noble, J.G. et al (2000) Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 163: 646-651.
60. Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thuroff, J. and Wein, A.J. (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766.
61. Morant, S.V., Reilly, K., Bloomfield, G.A. and Chapple, C. (2008) Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. Int J Clin Pract 62: 688-694.
62. Naglie, G., Radomski, S.B., Brymer, C., Mathiasen, K., O–Rourke, K. and Tomlinson, G. (2002) A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence. J Urol 167: 586-590.
63. Neuhaus, J., Weimann, A., Stolzenburg, J.U., Dawood, W., Schwalenberg, T. and Dorschner, W. (2002) Smooth muscle cells from human urinary bladder express connexin 43 in vivo and in vitro. World J Urol 20: 250-254.
64. Nickel, J.C. (2008) Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int 101(Suppl): 11-16.
65. Nishino, Y., Masue, T., Miwa, K., Takahashi, Y., Ishihara, S. and Deguchi, T. (2006) Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 97: 747-751.
66. Ockrim, J.L., Laniado, M.E., Patel, A., Tubaro, A. and St Clair Carter, S. (2001) A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. J Urol 166: 2221-2225.
67. O–Reilly, B.A., Kosaka, A.H., Chang, T.K., Ford, A.P., Popert, R. and McMahon, S.B. (2001) A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int 87: 617-622.
68. Ouslander, J.G. (2004) Management of overactive bladder. N Engl J Med 350: 786-799.
69. Paick, J-S., Ku, J.H., Shin, J.W., Yang, J.H. and Kim, S.W. (2006) α-Blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int 97: 1017-1023.
70. Peters, T.J., Donovan, J.L., Kay, H.E., Abrams, P., de la Rosette, J.J., Porru, D. et al (1997) The International Continence Society ‘Benign Prostatic Hyperplasia– Study: the bothersomeness of urinary symptoms. J Urol 157: 885-889.
71. Pontari, M.A., McNaughton-Collins, M., O–Leary, M.P., Calhoun, E.A., Jang, T., Kusek, J.W. et al; CPCRN Study Group (2005) A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 96: 559-565.
72. Roehrborn, C.G., McConnell, J.D., Barry, M.J., Benaim, E., Bruskewitz, R.C., Blute, M.L. et al (2003a) Guidelines on the Management of Benign Prostatic Hyperplasia. American Urological AssociationEducation and Research, Inc: Linthicum, MD.
73. Roehrborn, C.G., van Kerrebroeck, P. and Nordling, J. (2003b) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92: 257-261.
74. Roehrborn, C.G., Abrams, P., Rovner, E.S., Kaplan, S.A., Herschorn, S. and Guan, Z. (2006) Efficacy and safety of tolterodine extended-release in men with overactive bladder and urinary urgency incontinence. BJU Int 97: 1003-1006.
75. Roehrborn, C.G., Kaplan, S.A., Kraus, S.R., Wang, J.T., Bavendam, T. and Guan, Z. (2008) Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72: 1061-1067.
76. Rohrmann, S., Giovannucci, E., Willett, W.C. and Platz, E.A. (2007) Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 85: 523-529.
77. Rosenberg, M.T., Staskin, D.R., Kaplan, S.A., MacDiarmid, S.A., Newman, D.K. and Ohl, D.A. (2007) A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 61: 1535-1546.
78. Schneider, T., de la Rosette, J.J.M.C.H. and Michel, M.C. (2009) Nocturia: a non-specific but important symptom of urological disease. Int J Urol 16: 249-256.
79. Sexton, C.C., Coyne, K.S., Vats, V., Kopp, Z.S., Irwin, D.E. and Wagner, T.H. (2009) Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 15: S98-S107.
80. Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W., Abrams, P., Herzog, A.R., Corey, R. et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20: 327-336.
81. Stothers, L., Thom, D. and Calhoun, E. (2005) Urologic Diseases in America project: urinary incontinence in males - demographics and economic burden. J Urol 173: 1302-1308.
82. Suzuki, S., Platz, E.A., Kawachi, I., Willett, W.C. and Giovannucci, E. (2002) Intakes of energy and macro-nutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75: 689-697.
83. Takeda, H., Yamazaki, Y., Akahane, M., Igawa, Y., Ajisawa, Y. and Nishizawa, O. (2000) Role of the beta (3)-adrenoceptor in urine storage in the rat: comparison between the selective beta (3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther 293: 939-945.
84. Thomas, A.W., Cannon, A., Bartlett, E., Ellis-Jones, J. and Abrams, P. (2004) The natural history of voiding dysfunction in men: a study of the prevalence of detrusor instability. BJU Int 93(6): 745-750.
85. Tse, V., Wills, E., Szonyi, G. and Khadra, M.H. (2000) The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol 163: 535-539.
86. Turner, W.H. and Brading, A.F. (1997) Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis, and treatment. Pharmacol Ther 75: 77-110.
87. Wang, H.Z., Lee, S.W. and Day, N.S. (2001) Gap junction channel activity in cultured human smooth muscle cell pairs: gating and unitary conductances. Urology 57(Suppl 1): 111-112.
88. Yang, Y., Zhao, X.F., Li, H.Z., Wang, W., Zhang, Y., Xiao, H. et al (2007) Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 120: 370-374.
89. Yokoyama, T., Uematsu, K., Watanabe, T., Sasaki, K., Kumon, H. and Nagai, A. (2009) Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol April 24: [Epub ahead of print].
90. Yoshimura, N. and de Groat, W.C. (1997) Neural control of the lower urinary tract. Int J Urol 4: 111-125.
91. Yoshimura, N., Kaiho, Y., Miyazato, M., Yunoki, T., Tai, C., Chancellor, M.B. et al (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 377: 437-448.